Venus Remedies Limited (IN:VENUSREM)
:VENUSREM
Top Page
Venus Remedies Limited
(VENUSREM)
Select Model
Select Model
Rating:79Outperform
Price Target:
₹1,062.00
▲(35.76% Upside)
Action:ReiteratedDate:03/13/26
The score is driven primarily by strong financial performance (improving profitability, low leverage, and robust free cash flow). Technicals also support the rating with a clear uptrend and positive momentum, while valuation is supportive due to a low P/E.
Positive Factors
Free cash flow strength
Sustained positive free cash flow and a strong operating cash flow-to-net-income ratio provide durable funding for capex, working capital, dividends or buybacks, and R&D. This cash conversion resilience reduces refinancing risk and supports strategic investments over the next 2–6 months and beyond.
Negative Factors
Product/market concentration
Heavy concentration in hospital/critical-care and anti-infectives elevates exposure to hospital purchasing cycles, tender dynamics, antibiotic stewardship policies and regulatory scrutiny. Such concentration can amplify revenue volatility and limit resilience to structural shifts in hospital procurement.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow strength
Sustained positive free cash flow and a strong operating cash flow-to-net-income ratio provide durable funding for capex, working capital, dividends or buybacks, and R&D. This cash conversion resilience reduces refinancing risk and supports strategic investments over the next 2–6 months and beyond.
Read all positive factors
Venus Remedies Limited (VENUSREM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹12.34B
Dividend YieldN/A
Average Volume (3M)2.33K
Price to Earnings (P/E)10.0
Beta (1Y)0.50
Revenue Growth13.32%
EPS Growth218.38%
CountryIN
Employees1,187
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)19.14
Shares Outstanding13,366,988
10 Day Avg. Volume2,529
30 Day Avg. Volume2,330
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.75
Price to Sales (P/S)0.65
P/FCF Ratio5.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.9
Revenue Forecast (FY)₹828.20M
Venus Remedies Limited Business Overview & Revenue Model
Company Description
Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant,...
How the Company Makes Money
Venus Remedies makes money primarily by selling pharmaceutical products. Its main revenue stream is the manufacture and sale of finished formulations—especially hospital and critical-care medicines (notably anti-infectives/antibiotics)—to customer...
Venus Remedies Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
75
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.96B | 6.48B | 5.91B | 5.56B | 5.99B | 5.48B |
| Gross Profit | 2.76B | 1.66B | 2.18B | 2.25B | 2.00B | 1.07B |
| EBITDA | 1.18B | 944.10M | 711.80M | 703.46M | 701.40M | 968.49M |
| Net Income | 703.30M | 453.20M | 284.91M | 265.70M | 407.24M | 617.65M |
Balance Sheet | ||||||
| Total Assets | 7.68B | 7.16B | 6.27B | 6.01B | 5.80B | 5.56B |
| Cash, Cash Equivalents and Short-Term Investments | 2.36B | 1.64B | 838.05M | 720.77M | 432.56M | 288.79M |
| Total Debt | 143.80M | 16.90M | 413.25M | 422.90M | 428.45M | 513.18M |
| Total Liabilities | 1.74B | 1.55B | 1.39B | 1.41B | 1.39B | 1.56B |
| Stockholders Equity | 5.94B | 5.61B | 4.88B | 4.60B | 4.40B | 4.00B |
Cash Flow | ||||||
| Free Cash Flow | 682.20M | 812.90M | 278.40M | 288.02M | 272.94M | 1.25B |
| Operating Cash Flow | 811.10M | 909.20M | 372.85M | 366.20M | 410.01M | 1.33B |
| Investing Cash Flow | -1.27B | -807.90M | -72.09M | -508.30M | -166.26M | 557.16M |
| Financing Cash Flow | 126.70M | -9.50M | -10.83M | -5.70M | -94.77M | -1.62B |
Venus Remedies Limited Technical Analysis
Positive
782.25
Price Trends
781.30
Positive
745.88
Positive
606.03
Positive
Market Momentum
30.60
Positive
59.64
Neutral
39.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Positive. The current price of 782.25 is below the 20-day moving average (MA) of 838.72, above the 50-day MA of 781.30, and above the 200-day MA of 606.03, indicating a bullish trend. The MACD of 30.60 indicates Positive momentum. The RSI at 59.64 is Neutral, neither overbought nor oversold. The STOCH value of 39.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VENUSREM.
Venus Remedies Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹12.34B | 10.01 | ― | ― | 13.32% | 218.38% | |
63 Neutral | ₹3.28B | 19.99 | ― | ― | -5.82% | -59.22% | |
61 Neutral | ₹11.46B | 18.86 | ― | ― | -37.70% | -19.79% | |
56 Neutral | ₹4.66B | 34.53 | ― | ― | 32.95% | 67.39% | |
55 Neutral | ₹3.07B | 56.53 | ― | 0.26% | -9.16% | 49.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ₹2.25B | 7.63 | ― | ― | -30.27% | -3470.06% |
* Healthcare Sector Average
IN:VENUSREM
Venus Remedies Limited
923.40
622.05
206.42%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
140.40
57.72
69.81%
IN:KILITCH
Kilitch Drugs (India) Limited
133.40
-33.87
-20.25%
IN:MEDICAMEQ
Medicamen Biotech Limited
226.70
-264.33
-53.83%
IN:NECLIFE
Nectar Lifesciences Ltd.
10.02
-13.19
-56.83%
IN:ZIMLAB
Zim Laboratories Ltd.
67.31
-18.16
-21.25%
Venus Remedies Limited Corporate Events
Venus Remedies Alerts Shareholders to Special Window for Physical Share Transfer Requests
Mar 10, 2026
Venus Remedies has notified stock exchanges that it has used its official social media channels to inform shareholders about a special window for re-lodgement of transfer requests for physical shares. The communication aligns with recent Securitie...
Venus Remedies Publishes Unaudited Q3 FY2025 Financial Results in Newspapers
Jan 31, 2026
Venus Remedies Limited has notified the stock exchange that it has published its unaudited financial results for the period ended 31 December 2025 in newspapers, in compliance with disclosure requirements under Regulation 30 of the Listing Obligat...
Venus Remedies Closes Trading Window Ahead of December 2025 Results
Dec 23, 2025
Venus Remedies Limited has announced that, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, its trading window for dealing in the company’s securities will be closed for all designated persons from January 1, 2026 ...
Venus Remedies Opens Special Window for Share Transfer Requests
Dec 13, 2025
Venus Remedies Limited has announced the opening of a special window for the re-lodgement of transfer requests for physical shares. This move is in compliance with a SEBI circular issued in July 2025, and the company has communicated this update t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.